Clinical Reviews in Allergy & Immunology

, Volume 37, Issue 2, pp 58–66 | Cite as

Immune Response to FVIII in Hemophilia A: An Overview of Risk Factors



Development of inhibitors is perhaps the most serious complication of factor VIII (FVIII) replacement therapy, which can practically preclude efficient clinical management of patients with hemophilia A. Much effort therefore has been focused both in improving our understanding of the reasons for the formation of FVIII antibodies and to find alternative methods of treatment. Several patient-related factors have been related to the risk of inhibitor development such as ethnicity, FVIII gene mutation type, family history of inhibitors, HLA haplotype, polymorphisms in the promoter regions of IL 10 gene, single nucleotide polymorphisms of tumor necrosis factor alpha gene, and so on. In addition to the genetic determinants, there are several nongenetic factors which mainly include treatment characteristics like the type and purity of coagulation factor concentrates used for treatment, age at the time of initial treatment, initial doses of concentrate, mode of infusion, surgery, frequency of dosing prior to inhibitor development, and intensity of treatment or regular prophylaxis. Inflammatory processes in early childhood are under discussion as being an environmental factor that may modify the immune response to a foreign antigen. The genetic risks cannot be changed, while environmental factors may increase or decrease the inhibitor risk in an individual patient. In addition, there are other causes of inhibitor development against FVIII like stress, age, malignancy, infection, pregnancy, antibiotics, etc. Development of inhibitors in such cases happens in individuals who are not hemophilic and have normal plasma FVIII levels. Acquired inhibitors to FVIII in nonhemophiliacs (autoantibodies) pose a further challenge to treatment, as this is often associated with significant morbidity and mortality. Prognosis in case of autoantibodies is related to the underlying disease process and is associated with high mortality. Improved understanding of these complex interactions may lead to the development of preventive measures to minimize FVIII inhibitor formation. The modifiable risk factors for inhibitor formation may provide the key to predict and perhaps prevent the formation of inhibitors in hemophilia patients.


FVIII inhibitors Hemophilia A MHC haplotype Prophylaxis Acquired hemophilia 


  1. 1.
    Darby SC, Keeling DM, Spooner RJ et al (2004) The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2:1047–1054PubMedCrossRefGoogle Scholar
  2. 2.
    Chang H, Sher GD, Blanchette VS, Teitel JM (1999) The impact of inhibitors on the cost of clotting factor replacement therapy in haemophilia A in Canada. Haemophilia 5:247–252PubMedCrossRefGoogle Scholar
  3. 3.
    Prowse CV, MacGregor IR (1998) Neoantigens and antibodies to factor VIII. Blood Rev 12:99–105PubMedCrossRefGoogle Scholar
  4. 4.
    Ghosh K, Jijina F, Shetty S, Madkaikar M, Mohanty D (2002) First-time development of FVIII inhibitor in haemophilia patients during the postoperative period. Haemophilia 8:776–780PubMedCrossRefGoogle Scholar
  5. 5.
    Lavigne-Lissalde G, Tarrade C, Lapalud P et al (2008) Simultaneous detection and epitope mapping of anti-factor VIII antibodies. Thromb Haemost 99:1090–1096PubMedGoogle Scholar
  6. 6.
    Kopecky EM, Greinstetter S, Pabinger I, Buchacher A, Romisch J, Jungbauer A (2006) Mapping of FVIII inhibitor epitopes using cellulose-bound synthetic peptide arrays. J Immunol Methods 308:90–100PubMedCrossRefGoogle Scholar
  7. 7.
    Shetty S, Ghosh K, Mohanty D (2003) An ELISA assay for the detection of factor VIII antibodies - comparison with the conventional Bethesda assay in a large cohort of haemophilia samples. Acta Haematol 109:18–22PubMedCrossRefGoogle Scholar
  8. 8.
    Sultan Y (1992) Prevalence of inhibitors in a population of 3435 hemophilia patients in France. French Hemophilia Study Group. Thromb Haemost 67:600–602PubMedGoogle Scholar
  9. 9.
    Ehrenforth S, Kreuz W, Scharrer I et al (1992) Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339:594–598PubMedCrossRefGoogle Scholar
  10. 10.
    Lakich D, Kazazian HH Jr, Antonarakis SE, Gitschier J (1993) Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet 5:236–241PubMedCrossRefGoogle Scholar
  11. 11.
    Bagnall RD, Waseem N, Green PM, Giannelli F (2002) Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. Blood 99:168–174PubMedCrossRefGoogle Scholar
  12. 12.
    Jacquemin M, De Maeyer M, D’Oiron R, Lavend’Homme R, Peerlinck K, Saint-Remy JM (2003) Molecular mechanisms of mild and moderate hemophilia A. J Thromb Haemost 1:456–463PubMedCrossRefGoogle Scholar
  13. 13.
    Oldenburg J, Pavlova A (2006) Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 12(Suppl 6):15–22PubMedCrossRefGoogle Scholar
  14. 14.
    Viel KR, Machiah DK, Warren DM et al (2007) A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels. Blood 109:3713–3724PubMedCrossRefGoogle Scholar
  15. 15.
    Astermark J, Oldenburg J, Escobar M, White GC 2nd, Berntorp E (2005) The Malmo International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica 90:924–931PubMedGoogle Scholar
  16. 16.
    Liu ML, Shen BW, Nakaya S et al (2000) Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure. Blood 96:979–987PubMedGoogle Scholar
  17. 17.
    Boekhorst J, Lari GR, D’Oiron R et al (2008) Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations. Haemophilia 14:729–735Google Scholar
  18. 18.
    Repesse Y, Slaoui M, Ferrandiz D et al (2007) Factor VIII (FVIII) gene mutations in 120 patients with hemophilia A: detection of 26 novel mutations and correlation with FVIII inhibitor development. J Thromb Haemost 5:1469–1476PubMedCrossRefGoogle Scholar
  19. 19.
    Franchini M, Girelli D, Olivieri O et al (2006) Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A. Haemophilia 12:448–451PubMedCrossRefGoogle Scholar
  20. 20.
    Hay CR (1998) Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 4:558–563PubMedCrossRefGoogle Scholar
  21. 21.
    Goodeve A (2003) The incidence of inhibitor development according to specific mutations–and treatment? Blood Coagul Fibrinolysis 14(Suppl 1):S17–21PubMedCrossRefGoogle Scholar
  22. 22.
    Astermark J, Berntorp E, White GC, Kroner BL (2001) The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 7:267–272PubMedCrossRefGoogle Scholar
  23. 23.
    Yee TT, Pasi KJ, Lilley PA, Lee CA (1999) Factor VIII inhibitors in haemophiliacs: a single-centre experience over 34 years, 1964-97. Br J Haematol 104:909–914PubMedCrossRefGoogle Scholar
  24. 24.
    Hay CR (2006) The epidemiology of factor VIII inhibitors. Haemophilia 12(Suppl 6):23–28; discussion 28-9PubMedCrossRefGoogle Scholar
  25. 25.
    Aledort LM, Dimichele DM (1998) Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 4:68PubMedCrossRefGoogle Scholar
  26. 26.
    Bouma BN, van Mourik JA, Wiegerinck Y, Sixma JJ, Mochtar IA (1973) Immunological characterization of anti-haemophilic factor A related antigen in haemophilia A. Scand J Haematol 11:184–187PubMedGoogle Scholar
  27. 27.
    Kavanagh ML, Wood CN, Davidson JF (1981) The immunological characterization of human antibodies to factor VIII isolated by immuno-affinity chromatography. Thromb Haemost 45:60–64PubMedGoogle Scholar
  28. 28.
    Moffat EH, Bloom AL, Jones J, Matthews N, Newcombe RG (1985) A study of cell mediated and humoral immunity in haemophilia and related disorders. Br J Haematol 61:157–167PubMedCrossRefGoogle Scholar
  29. 29.
    Reding MT, Wu H, Krampf M et al (1999) CD4 + T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects. Thromb Haemost 82:509–515PubMedGoogle Scholar
  30. 30.
    Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK (2006) Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 107:3167–3172PubMedCrossRefGoogle Scholar
  31. 31.
    Wilson AG, di Giovine FS, Blakemore AI, Duff GW (1992) Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1:353PubMedCrossRefGoogle Scholar
  32. 32.
    Bouma G, Crusius JB, Oudkerk Pool M et al (1996) Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 43:456–463PubMedCrossRefGoogle Scholar
  33. 33.
    Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW (1993) An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 177:557–560PubMedCrossRefGoogle Scholar
  34. 34.
    Lippert LE, Fisher LM, Schook LB (1990) Relationship of major histocompatibility complex class II genes to inhibitor antibody formation in hemophilia A. Thromb Haemost 64:564–568PubMedGoogle Scholar
  35. 35.
    Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EG, Simpson E (1997) HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 77:238–242PubMedGoogle Scholar
  36. 36.
    Hay CR, Ollier W, Pepper L et al (1997) HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost 77:234–237PubMedGoogle Scholar
  37. 37.
    Goudemand J, Rothschild C, Demiguel V et al (2006) Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 107:46–51PubMedCrossRefGoogle Scholar
  38. 38.
    Ettingshausen CE, Kreuz W (2006) Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia 12(Suppl 6):102–106PubMedCrossRefGoogle Scholar
  39. 39.
    Tagariello G, Zanotto D, Radossi P, Sartori R, Belvini D, Salviato R (2007) In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates. Am J Hematol 82:460–462PubMedCrossRefGoogle Scholar
  40. 40.
    Hausl C, Ahmad RU, Sasgary M et al (2005) High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. Blood 106:3415–3422PubMedCrossRefGoogle Scholar
  41. 41.
    Santagostino E, Mancuso ME, Rocino A et al (2005) Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 130:422–427PubMedCrossRefGoogle Scholar
  42. 42.
    Gouw SC, van der Bom JG, van den Berg HM (2007) Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 109:4648–4654PubMedCrossRefGoogle Scholar
  43. 43.
    Ghosh K, Shetty S, Kulkarni B et al (2001) Development of inhibitors in patients with haemophilia from India. Haemophilia 7:273–278PubMedCrossRefGoogle Scholar
  44. 44.
    Zanon E, Zerbinati P, Girolami B, Bertomoro A, Girolami A (1999) Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates. Blood Coagul Fibrinolysis 10:117–120PubMedCrossRefGoogle Scholar
  45. 45.
    Collins P, Macartney N, Davies R, Lees S, Giddings J, Majer R (2004) A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br J Haematol 124:86–90PubMedCrossRefGoogle Scholar
  46. 46.
    Cohen AJ, Kessler CM (1996) Acquired inhibitors. Baillieres Clin Haematol 9:331–354PubMedCrossRefGoogle Scholar
  47. 47.
    Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A (2003) Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 121:21–35PubMedCrossRefGoogle Scholar
  48. 48.
    Green D, Lechner K (1981) A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemastos 45(3):200–203Google Scholar
  49. 49.
    Morrison AE, Ludlam CA, Kessler C (1993) Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 81:1513–1520PubMedGoogle Scholar
  50. 50.
    Sallah S, Nguyen NP, Abdallah JM, Hanrahan LR (2000) Acquired hemophilia in patients with hematologic malignancies. Arch Pathol Lab Med 124:730–734PubMedGoogle Scholar
  51. 51.
    Sallah S, Wan JY (2001) Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients. Cancer 91:1067–1074PubMedCrossRefGoogle Scholar
  52. 52.
    Hauser I, Schneider B, Lechner K (1995) Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment. Thromb Haemost 73:1–5PubMedGoogle Scholar
  53. 53.
    Pavlova A, Diaz-Lacava A, Zeitler H et al (2008) Increased frequency of the CTLA-4 49 A/G polymorphism in patients with acquired haemophilia A compared to healthy controls. Haemophilia 14:355–360PubMedCrossRefGoogle Scholar
  54. 54.
    Franchini M (2006) Postpartum acquired factor VIII inhibitors. Am J Hematol 81:768–773PubMedCrossRefGoogle Scholar
  55. 55.
    Shobeiri SA, West EC, Kahn MJ, Nolan TE (2000) Postpartum acquired hemophilia (factor VIII inhibitors): a case report and review of the literature. Obstet Gynecol Surv 55:729–737PubMedCrossRefGoogle Scholar
  56. 56.
    Michiels JJ, Hamulyak K, Nieuwenhuis HK, Novakova I, van Vliet HH (1997) Acquired haemophilia A in women postpartum: management of bleeding episodes and natural history of the factor VIII inhibitor. Eur J Haematol 59:105–109PubMedGoogle Scholar
  57. 57.
    Triplett DA, Asherson RA (2000) Pathophysiology of the catastrophic antiphospholipid syndrome (CAPS). Am J Hematol 65:154–159PubMedCrossRefGoogle Scholar
  58. 58.
    Harris EN, Pierangeli SS (2000) ‘Equivocal’ antiphospholipid syndrome. J Autoimmun 15:81–85PubMedCrossRefGoogle Scholar
  59. 59.
    Small P (1988) Severe hemorrhage in a patient with circulating anticoagulant, acquired hypoprothrombinemia, and systemic lupus erythematosus. Arthritis Rheum 31:1210–1211PubMedCrossRefGoogle Scholar
  60. 60.
    Blanco AN, Cardozo MA, Candela M, Santarelli MT, Perez Bianco R, Lazzari MA (1997) Anti-factor VIII inhibitors and lupus anticoagulants in haemophilia A patients. Thromb Haemost 77:656–659PubMedGoogle Scholar
  61. 61.
    Saxena R, Dhot PS, Saraya AK, Singh H, Malhotra OP (1993) Simultaneous occurrence of factor VIIIC inhibitor and lupus anticoagulant. Am J Hematol 42:232–233PubMedCrossRefGoogle Scholar
  62. 62.
    Biron C, Durand L, Lemkecher T et al (1996) Simultaneous occurrence of lupus anticoagulant, factor VIII inhibitor and localized pemphigoid. Am J Hematol 51:250–251PubMedCrossRefGoogle Scholar
  63. 63.
    Nuss R, Jacobson L, Hathaway WE, Manco-Johnson M (1999) Evidence for antiphospholipid antibodies in hemophilic children with factor VIII inhibitors. Recombinate PUP Study Group. Thromb Haemost 82:1559–1560PubMedGoogle Scholar
  64. 64.
    Ballard HS, Nyamuswa G (1993) Life-threatening haemorrhage in a patient with rheumatoid arthritis and a lupus anticoagulant coexisting with acquired autoantibodies against factor VIII. Br J Rheumatol 32:515–517PubMedCrossRefGoogle Scholar
  65. 65.
    Lindhoff-Last E, Humpich M, Schmitt J, Rodiger S, Seifried E, Bauersachs R (2002) MIXCON-LA: a precise, sensitive and specific aPTT-based assay for detection of lupus anticoagulant. Clin Appl Thromb Hemost 8:163–167PubMedCrossRefGoogle Scholar
  66. 66.
    Candore G, Campagna AM, Cuppari I, Di Carlo D, Mineo C, Caruso C (2007) Genetic control of immune response in carriers of the 8.1 ancestral haplotype: correlation with levels of IgG subclasses: its relevance in the pathogenesis of autoimmune diseases. Ann NY Acad Sci 1110:151–158PubMedCrossRefGoogle Scholar
  67. 67.
    Mehra NK, Kaur G, Kanga U, Tandon N (2002) Immunogenetics of autoimmune diseases in Asian Indians. Ann NY Acad Sci 958:333–336PubMedCrossRefGoogle Scholar
  68. 68.
    Madkaikar M, Ghosh K (2003) Treating patients of myelodysplastic syndrome with antithymocytic globulin—should we be more selective? Blood 102:3851–3852; author reply 3852PubMedCrossRefGoogle Scholar
  69. 69.
    Vanderlugt CL, Begolka WS, Neville KL et al (1998) The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Immunol Rev 164:63–72PubMedCrossRefGoogle Scholar
  70. 70.
    Alumkal J, Rice L, Vempathy H, McCarthy JJ, Riggs SA (1999) Surgery-associated factor VIII inhibitors in patients without hemophilia. Am J Med Sci 318:350–352PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  1. 1.National Institute of ImmunohaematologyMumbaiIndia

Personalised recommendations